Gapping up
In reaction to strong earnings/guidance:
- SHW +0.9%, DBD +0.5%
Other news:
- THTX +39.6% (announces data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology at AACXR)
- HOOK +16% (announces 'positive' results on its prophylactic Cytomegalovirus (CMV) vaccine candidate HB-101)
- SPCE +13.7% (signs space act agreement with NASA for private orbital spaceflight to the international space station)
- ALT +8.1% (FDA has cleared its IND application to conduct a Phase 2 trial of HepTcell for the treatment of chronic hepatitis B)
- CIDM +7.7% (partners with Team Whistle; announces multi-film deal with Glass House Distribution )
- NIO +7.4% (Tencent (TCEHY) confirmed increased active stake fo 15.1%)
- AGEN +4.4% (enters agreement with Betta Pharma for an exclusive collaboration and license agreement for the development and commercialization of balstilimab and zalifrelimab in Greater China)
- XCUR +4% (presents updated pharmacodynamic and safety data at the AACR Virtual Annual Meeting)
- PCG +3.7% (Achieves bankruptcy court confirmation of its plan of reorganization; expects to emerge from Chapter 11 in July)
- PAYS +3.6% (files for 1,514,166 share common stock offering by selling shareholders)
- SUPV +3.1% (announces that Founder Patricio Supervielle will resume role as CEO)
- PUMP +2.2% (completes review process and files formerly delinquent 2019 annual and quarterly reports - did not identify any items that would require revision or restatement)
- HCKT +1.5% (to pay dividends on a quarterly basis; declares quarterly dividend of $0.095/share)
- AGTC +1.5% (provided an update on the continued productivity and quality improvements made in its proprietary manufacturing platform that is currently being used to create clinical trial material for the Company's planned pivotal clinical trials in X-linked retinitis pigmentosa)
- AUPH +1.3% (confirmed the FDA approved the New Drug Application for GIMOTI )
- TAK +1% (provides update of the financial impact of the European Commission's decision to release TAK from commitment to divest Shire's (SHPG) pipeline compound SHP647)
Analyst comments:
- GPS +6.1% (upgraded to Overweight from Underweight at Wells Fargo)
- TS +2.2% (upgraded to Buy from Sell at Goldman)
- CAG +1.6% (upgraded to Buy from Hold at Jefferies)
- DKNG +1.5% (initiated with a Buy at Jefferies)
- ALGT +1.2% (upgraded to Strong Buy from Outperform at Raymond James)
- WMT +1% (upgraded to Buy at UBS)
- HLT +0.9% (upgraded to Overweight from Equal Weight at Barclays)
- JCI +0.9% (upgraded to Buy from Neutral at UBS)
- CPB +0.8% (upgraded to Buy from Hold at Jefferies)